Your browser doesn't support javascript.
loading
IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
Zhang, Yinghui; Wester, Lynn; He, Jichao; Geiger, Tamar; Moerkens, Marja; Siddappa, Ram; Helmijr, Jean A; Timmermans, Mieke M; Look, Maxime P; van Deurzen, Caroline H M; Martens, John W M; Pont, Chantal; de Graauw, Marjo; Danen, Erik H J; Berns, Els M J J; Meerman, John H N; Jansen, Maurice P H M; van de Water, Bob.
Affiliation
  • Zhang Y; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. y.zhang@lacdr.leidenuniv.nl.
  • Wester L; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • He J; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • Geiger T; Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Moerkens M; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • Siddappa R; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • Helmijr JA; Department of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
  • Timmermans MM; Department of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
  • Look MP; Department of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
  • van Deurzen CHM; Department of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
  • Martens JWM; Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Pont C; Department of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
  • de Graauw M; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • Danen EHJ; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • Berns EMJJ; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • Meerman JHN; Department of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
  • Jansen MPHM; Division of Toxicology, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • van de Water B; Department of Medical Oncology and Cancer Genomic Netherlands, Rotterdam, The Netherlands.
Oncogene ; 37(14): 1869-1884, 2018 04.
Article in En | MEDLINE | ID: mdl-29353882
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Receptors, Somatomedin / Drug Resistance, Neoplasm / Antineoplastic Agents, Hormonal / Estrogen Antagonists / P21-Activated Kinases / Rho Guanine Nucleotide Exchange Factors Type of study: Prognostic_studies Limits: Female / Humans Language: En Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Breast Neoplasms / Receptors, Somatomedin / Drug Resistance, Neoplasm / Antineoplastic Agents, Hormonal / Estrogen Antagonists / P21-Activated Kinases / Rho Guanine Nucleotide Exchange Factors Type of study: Prognostic_studies Limits: Female / Humans Language: En Year: 2018 Type: Article